Viral Resistance Increase Due To Denavir Switch Unlikely - SB Expert
This article was originally published in The Tan Sheet
Executive Summary
The proposed Rx-to-OTC switch of SmithKline Beecham's Denavir (penciclovir 1%) would "not cause any topical change in antiviral resistance," predicted Myron Levin, MD, University of Colorado Health Sciences Center, at a Dec. 1 joint review of the drug's switch potential by FDA's Nonprescription and Antiviral Drugs Advisory Committees.